yeb4432 wrote:
Switching between the ABCRs you are not moving up in effectiveness by switching, Ultimately you are getting the same thing folks, obviously in a different package. Bottom line is that all injectables are ONLY BOUT 30% EFFECTIVE!
I don't believe that this statement is correct. There are differences between the CRAB medications. First off, there's Copaxone vs. the Ifn-B's. In addition, even between the different interferons there are important differences. For example, Betaseron is produced in bacteria. As a result, the interferon-B protein IS NOT glycosylated, i.e., it does not have any sugar groups attached to it. In contrast, Avonex and Rebif are produced in mammalian cells. As such, the protein IS glycosylated which makes it identical to the interferon-B naturally produced in our bodies. The lack of glycosylation in Betaseron increases the immunogenicty of the protein and makes it more likely that one would produce neutralizing antibodies against it diminishing its effectiveness. The incidence of neutralizing antibodies is much lower in Avonex.
Another difference lies in the injection method. Both Betaseron and Rebif are delivered via a subcutaneous injection while Avonex is given via an intramuscular injection. When I was first diagnosed in 1999, the doctor's prescribing information for Betaseron described the injection site reactions as "injection site tissue necrosis". After 8.5 years of Avonex, I have only experienced some minor bruising probably less then half a dozen times and the bruises usually clear up after a few days. The absorption is also higher with a intramuscular injection then a subcutaneous injection, i.e., about 80% vs. 40%; information which must be taken into account when comparing the dosage differences between the different formulations.
In addition, the doctor's prescribing information for Copaxone stated that it was found to be clastogenic in a mutagenesis assay. This means that it caused breaks in the DNA of the test cells. It is my belief that this action might be related to the lipoatrophy problems which are often seen in people using Copaxone. It may be the case that the subdermal fat tissue is sensitive to Copaxone and that DNA damage is inducing the cells to go into apoptosis.
Quote:
After Copaxone, Tysabri is the safest MS med.
Again, I don't believe that this is correct. While I have not done an exhaustive literature search, I have yet to read about a case of PML in anyone that was on Ifn-B as their sole treatment.
Lastly, I will agree with you that none of the CRAB drugs are an ideal solution as their effectiveness is limited. However, as I have noted, there are important differences between them.
NHE